COVID-19 can disrupt your immune system in several ways, both during the infection and sometimes for months afterward. The disruption ranges from temporary drops in key immune cells to longer-lasting patterns of immune exhaustion and chronic inflammation, particularly in people who develop long COVID. For most people, the immune system recovers within a few months. But for a significant minority, the effects linger in ways researchers are still working to fully understand.
How the Virus Disrupts Immune Cells
One of the most distinctive features of COVID-19 is how sharply it reduces lymphocytes, the white blood cells (including T cells and B cells) that form the backbone of your adaptive immune response. This drop in lymphocyte counts, called lymphopenia, happens through several overlapping mechanisms.
The infection triggers a flood of inflammatory signaling molecules, often called a cytokine storm. This wave of inflammation shifts cell metabolism toward a more acidic state and directly triggers programmed cell death in T cells. At the same time, certain inflammatory signals cause neutrophils (a different type of immune cell) to actively suppress lymphocyte growth. The result is a two-pronged attack: your immune cells are being killed off while their replacement is being blocked.
The virus also reshapes how your bone marrow produces new immune cells. Normally, bone marrow maintains a balance between different cell lines. During severe COVID-19, production skews heavily toward cells involved in immediate inflammation while depleting the precursors that would become new lymphocytes. This means your body’s ability to replenish the very cells it’s losing is compromised at the source.
There’s also evidence that the virus can directly infect T cells. Even though T cells have low levels of the main receptor the virus uses to enter cells, cholesterol-rich patches on activated T cells may give the virus an alternative way in.
The Virus Sabotages Early Warning Systems
Your body’s first line of defense against any virus is the interferon response, a rapid alarm system that tells neighboring cells to activate their antiviral defenses. SARS-CoV-2 is remarkably good at dismantling this system from multiple angles.
The virus hides its genetic material inside double-membrane bubbles derived from your own cell structures, making it harder for your cells’ virus-detection sensors to spot it. Multiple viral proteins then attack the signaling chain at nearly every step. Some clip the sensors themselves, others block the relay signals, and still others prevent the final alarm message from reaching the cell nucleus where it would activate defense genes. One viral protein even parks itself at the nuclear pore, physically trapping immune-related messages inside the nucleus so they never get translated into proteins.
Perhaps most aggressively, one viral protein binds directly to the ribosome, the cell’s protein-making machinery, effectively shutting down the cell’s ability to produce any new proteins, including the interferons it desperately needs. This comprehensive suppression of early immune signaling is part of why the virus can gain such a strong foothold before the body mounts an effective response.
T Cell Exhaustion in Long COVID
For people who recover quickly, immune markers generally return to baseline within three to four months. But in people with long COVID, researchers have found a pattern that looks quite different: the immune system doesn’t return to normal. Instead, it gets stuck in a state of simultaneous overactivation and exhaustion.
A study published in Nature Immunology found that people with long COVID had virus-specific killer T cells that preferentially expressed PD-1 and CTLA-4, two surface markers that indicate a cell has been driven to exhaustion. Think of it like a car with the accelerator and brake pressed at the same time. These T cells have been activated so persistently that they’ve entered a dysfunctional state where they can neither fight effectively nor stand down. The same study found higher levels of virus-specific antibodies in long COVID patients and a notable mismatch between their T cell and B cell responses, suggesting the adaptive immune system has lost its normal coordination.
Research from a cohort of 142 individuals confirmed these findings and added important detail. People with long COVID showed persistent activation of inflammatory and immune exhaustion pathways for more than 180 days after their initial infection. Elevated levels of a key inflammatory signaling molecule (the IL-6 receptor) remained significantly higher in long COVID patients compared to both recovered individuals and uninfected controls. Upregulation of complement, metabolic disruption, and proinflammatory gene expression were all features that persisted well beyond the acute illness, alongside downregulation of natural killer cell receptors and T cell activation markers.
Autoantibodies After Infection
COVID-19 also appears to trigger the immune system to produce antibodies against the body’s own tissues. A meta-analysis found that roughly 25% of COVID-19 patients tested positive for antinuclear antibodies, compared to about 12% of controls. Antibodies against blood vessel lining cells were found in about 17% of patients versus 9% of controls. Antibodies associated with inflammation of blood vessels appeared in nearly 9% of patients, compared to less than 1% of controls.
These autoantibodies don’t necessarily mean someone will develop a full autoimmune disease. But their elevated presence suggests the intense immune activation during COVID-19 can blur the line between “self” and “foreign” in ways that may contribute to lingering symptoms or, in some cases, trigger new autoimmune conditions.
Immunosuppression and Infection Risk
The picture of COVID-19’s immune impact is not simply one of overactivation. Research has revealed that the virus creates a paradox: hyperinflammation and immunosuppression happening simultaneously. In more severe cases, the immune system can enter a profoundly suppressed state even as inflammatory markers remain elevated.
COVID-associated lymphopenia stands out from similar drops seen in other respiratory infections like influenza for both its severity and how long it persists. This suppression is clinically significant. Lymphopenia during COVID-19 is a strong predictor of poor outcomes and a major risk factor for secondary hospital-acquired infections, which account for an estimated 50% of COVID-related deaths in hospitalized patients.
How Vaccination Changes the Picture
Vaccination before infection appears to reduce the immune dysregulation that follows COVID-19. In a study of over 500 people with varying infection histories, those with ongoing long COVID symptoms who had received one or two vaccine doses showed lower levels of key inflammatory molecules compared to unvaccinated long COVID patients. This reduction correlated with fewer persistent gastrointestinal symptoms.
Importantly, the study found no evidence that vaccination itself caused the kind of immune disruption seen in long COVID. Uninfected people who received initial or booster doses showed no signs of the inflammatory cytokine patterns associated with post-COVID conditions. Vaccination produced strong antibody responses without triggering the dysfunctional immune signature.
Recovery Timeline
For most people, the active immune response from a COVID-19 infection calms down within three to four months. Lymphocyte counts rebound, inflammatory markers settle, and the immune system returns to its normal surveillance state. This is broadly similar to recovery from other significant viral infections, though the depth of immune disruption during COVID-19 tends to be more pronounced.
For the subset of people who develop long COVID, immune abnormalities can persist for six months to well over a year. The chronic inflammation, T cell exhaustion, and elevated inflammatory signaling documented in research cohorts were still present at the 180 to 365 day mark. Whether these changes eventually resolve in all patients, or whether some people experience permanent shifts in immune function, remains an open question. Children who develop multisystem inflammatory syndrome (MIS-C) after COVID-19 generally recover well. Heart-related complications typically resolve within six months, and cognitive effects like difficulty focusing or organizing usually clear by two years.
The overall picture is that COVID-19 does disrupt the immune system, sometimes substantially. For most people, the disruption is temporary. For those with prolonged symptoms, the immune system appears to settle into a state of chronic, low-grade dysfunction rather than suffering a single catastrophic injury. The damage isn’t like a broken bone. It’s more like a thermostat stuck at the wrong setting, keeping the system running in a way it wasn’t designed to sustain.